{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4M_bk9UKDA","lastupdate":"2023-11-24T00:00:00.000Z","update_date":"2023-11-24T00:00:00.000Z","lastModified":"Nov 24, 2023","active":1,"confidence_score":90,"confidence_score_reason":"markets, not claimed","urlname":"neuromagen","minimal_profile":null,"status":"","fullstatus":"","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$YrmQfKyyhQ3IhVcQz0rKLzEebtD5ioO9QNNnZpG9XfBA9xgb1UNmHP","name":"Neuromagen Pharma","oneliner":"Novel Drugs for Neurodegenerative Diseases","registrar":"516401254","website":"https://www.neuromagen.com/","careerspage":"","founded_month":5,"founded_year":2021,"formernames":[],"sociallinks":{"twitter":"","youtube":"","facebook":"","linkedin":"https://www.linkedin.com/company/80297359","instagram":""},"social":["https://www.linkedin.com/company/80297359"],"flattenedsociallinks":"https://www.linkedin.com/company/80297359","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":null,"employees":"1-10","employees_exact":4,"patent":1,"raised":2500000,"stage":"Seed","public_stage":"Seed","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":["Neuro-Magen","Neuro.Magen","NeuroMagen Therapeutics"],"about":"Neuromagen Pharma is a pharmaceutical company developing a new class of innovative small molecules that activate telomerase reverse transcriptase (TERT), an enzyme that plays a major role in preventing cellular senescence.\n\nThe companys mission is to develop drugs to delay the onset and the progression of neurodegenerative diseases such as ALS and to improve and extend patients lives.\n\nNeuromagen Pharma received FDA Orphan Drug Designation for its AGS-499 Drug Candidate to Slow the Progression of ALS (Amyotrophic Lateral Sclerosis).","climatetech_description":null,"is_climatetech_relevant":null,"phone":"","country":null,"address":{"israeli":[{"id":"4edbdd11-729d-42a6-bf03-9b8a9429a53b","city":"Be'er Sheva","type":null,"address":"HaEnergia Street 77, Be'er Sheva, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":null},"headquarter_address":null,"district":"South District","news":[{"id":"91LSWwTWYqtoPNp8KBu06QfIZA9o9da46Qj8ItZfYMvjTBjF307XCD","date":"Jun 23, 2022","link":"https://www.prnewswire.com/news-releases/neuromagen-pharma-announces-the-appointment-of-professor-gal-ifergane-head-of-the-neurology-department-at-soroka-medical-center-to-its-scientific-advisory-board-301573619.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Scientific Advisory Board, drug development","company":"Neuromagen Pharma Ltd.","layoffs":null,"summary":"Neuromagen Pharma has established a Scientific Advisory Board and appointed Prof. Gal Ifergane as its first member. The company is developing a new class of drugs for degenerative and senescence-associated diseases. Prof. Iferganes expertise in neurology will be valuable as the company moves towards clinical trials. Neuromagens lead drug candidate is AGS-499, which activates telomerase reverse transcriptase (TERT) and shows promise in treating neurodegenerative diseases, type 1 diabetes, fertility, and cardiovascular diseases. The company aims to submit an IND and conduct a First-in-Human Clinical Study for AGS-499. Prof. Ifergane is based in Beer Sheva, Israel, and has a strong background in clinical neurology and research. Neuromagen Pharma is focused on leveraging digital and biomed technologies for medical care.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["Scientific Advisory Board","AGS-499","Neurology","Telomerase activators","Drug development"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Management Changes"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Gcr8ev4JNrElmGjW81H1jOy4SwAT3upvL8YUeSQk7LvkGGI6W7vwWs","news_summary":"Neuromagen Pharma Announces the Appointment of Professor Gal Ifergane, Head of the Neurology Department at Soroka Medical Center, to its Scientific Advisory Board","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"HqRYsI4A2Ec3AodSTFZlIGJPNdw6bFeuNSlnnYiOCBpRp1C1XhYxaL","date":"May 5, 2022","link":"https://www.biospace.com/article/neuromagen-pharma-ltd-receives-fda-orphan-drug-designation-for-its-ags-499-drug-candidate-to-slow-the-progression-of-als-amyotrophic-lateral-sclerosis-/","source":"www.biospace.com","visible":1,"analysis":{"tags":"FDA Orphan Drug Designation","company":"Neuromagen Pharma Ltd.","layoffs":null,"summary":"Neuromagen Pharma has received FDA Orphan Drug Designation for its lead drug candidate, AGS-499, which has shown effectiveness in delaying the onset and progression of ALS. The designation provides seven years of marketing exclusivity for AGS-499. The drug activates telomerase reverse transcriptase (TERT) and has demonstrated efficacy in ALS, Alzheimers, diabetes, fertility, and cardiovascular disease. Neuromagen plans to begin clinical trials for AGS-499 and is pursuing collaborations with pharmaceutical partners in other therapeutic areas.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["FDA Orphan Drug Designation","AGS-499","Neurogenesis","Neuroprotective effects","Telomerase"],"date_of_event":"May 5, 2022","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers","Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Customers  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"kcCdFjhKzySJlW8M6BWWu66q3C94wxTJCao1bYb5BaySLATffMLBUs","news_summary":"Neuromagen Pharma Ltd. Receives FDA Orphan Drug Designation for its AGS-499 Drug Candidate to Slow the Progression of ALS (Amyotrophic Lateral Sclerosis) | BioSpace","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"24dfdb1a-81d9-4f9f-933b-52d169cbbb66","date":"Mar 21, 2022","link":"https://www.prnewswire.com/il/news-releases/neuromagen-pharma-announces-the-approval-of-a-nis-1-8m-budget-from-the-israel-innovation-authority-rd-fund-incentive-program-301506255.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"grant approval","company":"Neuromagen Pharma Ltd.","layoffs":null,"summary":"Neuromagen Pharma has received approval from the Israel Innovation Authority for a NIS 1.3 million grant to support the development of their lead drug candidate, AGS-499. The grant will be used for IND submission and first-in-human clinical trials, expected in 2024. AGS-499 is a small molecule activator of telomerase reverse transcriptase, which has shown promising effects in delaying the onset and progression of ALS. The approval of the grant is seen as a mark of quality for Neuromagens science and team. The company will also be presenting at the BIO-Europe Spring partnering conference.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["grant approval","drug development","clinical trials","telomerase reverse transcriptase","neurodegenerative diseases"],"date_of_event":"March 21, 2022","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"2Z4sh2pdz3ovet3G5kdwBxio7Ced5QwK2GeG4EtDZ786AOzJLgdrVZ","news_summary":"Neuromagen Pharma Announces the Approval of a NIS 1.8M Budget from the Israel Innovation Authority R&D Fund Incentive Program","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"KM4PctvLJcenYWiJ82nQv15Opqw0dVEhCS0G3m9p37C2RZivC5mZyp","date":"Feb 8, 2022","link":"https://www.prnewswire.com/news-releases/neuromagen-pharma-to-present-at-the-bio-europe-spring-2022-conference-301477634.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"drug development","company":"Neuromagen Pharma Ltd.","layoffs":null,"summary":"Neuromagen Pharma Ltd., a company developing telomerase-targeting drugs for degenerative and senescence-associated diseases, will provide an overview at the BIO-Europe Spring partnering conference. The company is developing patent-protected small molecules that activate telomerase reverse transcriptase, an aging-related enzyme. Their lead drug candidate, AGS-499, has shown efficacy in models of ALS and other degenerative conditions. Neuromagen is seeking collaborations to advance their non-core therapeutic areas. The companys CEO expressed excitement about presenting at the conference and engaging in partnering discussions. Neuromagen Pharma is an early-stage pharmaceutical company focused on developing innovative small molecules that activate telomerase.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["telomerase-targeting drugs","degenerative diseases","senescence-associated diseases","BIO-Europe Spring partnering conference","small molecules"],"date_of_event":"March 28-31, 2022","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Expand"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"ong8gFBs3qwx72V4VXOgflKW0VsPP5L2ywxSUsUlqyaQBmJRqUTmEp","news_summary":"Neuromagen Pharma to Present at the BIO-Europe Spring 2022 Conference","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"9a2c7c32-c052-4855-903a-35d760297e02","date":"Nov 2, 2021","link":"https://www-timesofisrael-com.cdn.ampproject.org/c/s/www.timesofisrael.com/israeli-drug-that-slowed-alzheimers-als-in-mice-gets-funding-to-start-trials/amp/","source":"www-timesofisrael-com.cdn.ampproject.org","visible":1,"analysis":{"tags":"drug development","company":"Neuromagen Pharma","layoffs":null,"summary":"Israeli-designed molecules that have shown effectiveness in delaying Alzheimers and amyotrophic lateral sclerosis in mice are set to begin the approval process for human use. The molecules were developed by Prof. Esther Priel and her colleagues at Ben Gurion University of the Negev, who formed the company Neuromagen Pharma. The company recently secured a multi-million-dollar investment from an unidentified Israeli funder, allowing them to move forward with clinical trials. The drug is expected to delay the onset and progression of the diseases and improve the quality of life. The specific amount of the investment was not disclosed.","partners":null,"customers":null,"investors":"unidentified Israeli funder","confidence":8,"key_topics":["Alzheimers","amyotrophic lateral sclerosis","mice","pre-clinical trials","investment"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"multi-million dollars","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"it3mDvR7aIPEiJW2Cqg7BVQy9ozpmhdjkJ3WuOdKEOZjPw6n41DQdQ","news_summary":"Israeli drug that slowed Alzheimer's, ALS in mice gets funding to start trials","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":5,"techcommunityinvolvement":null,"mediagallery":[{"id":"194340b6-87e9-4bc4-a692-319604205b84","timestamp":"2021-07-05 10:39:22.000000","resources_type":2,"resources_title":"","resources_file_name":"Wrec13WEU7E","alt":"","imageurl":"https://img.youtube.com/vi/Wrec13WEU7E/0.jpg","url":"http://youtu.be/Wrec13WEU7E"}],"tags":["pharmaceuticals","amyotrophic-lateral-sclerosis-(als)","degenerative-diseases","drug-development","cells"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA"],"technologysuccessstory":null,"usecases":[],"businessmodels":["B2B"],"productstage":"R&D","products":["AGS-499","AGS-534","AGS-500"],"geomarkets":[],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":0,"lastfunding":"$500K","totalrounds":2,"fundingstage":"Seed","totalfunding":"$2.5M","publicinvestors":0,"lastpublicfunding":500000,"totalpublicrounds":2,"totalpublicfunding":2500000},"team":[{"name":"Gil Ben-Menachem","email":"gil@neuromagen.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4M_bk9UJDA","bounced":true,"claimed":0,"founder":1,"urlname":"gil-ben-menachem-1","visible":0,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgr4rcxAoM","position":"Co-founder & CEO","last_name":"Ben-Menachem","claimtoken":"4nYZQeqxARDQvJ8rHBNWOzY4N3vprjG646HPnpSRNwPPj4er0X9ZZ0","first_name":"Gil","picturekey":"$V99iuS9BbcarYvTtJRFXpvhBDEDYFLFtRErxEqQXjGa7SOUnDKIoG2","claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/gil-ben-menachem-8ba440/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2022-09-12 12:16:05.000000","initials":"","pictureurl":"https://storage.googleapis.com/clean-finder-353810/$V99iuS9BbcarYvTtJRFXpvhBDEDYFLFtRErxEqQXjGa7SOUnDKIoG2","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"private-visibility","visibilityTooltip":"tooltip tooltip-html-content='<style>\n    .visibility-tooltip-container {\n        display: flex;\n        column-gap: 0.8rem;\n        padding: 0.8rem 1rem;\n        align-items: center;\n    } \n\n    .visibility-tooltip-container text {\n        font-size: 1.4rem;\n        text-transform: capitalize;\n        font-weight: 500;\n    }\n</style>\n\n<div class=\"visibility-tooltip-container\">\n    <img height=\"20\" width=\"20\" style=\"display: flex\" src=\"/assets/private-visibility.svg\"/>\n    <img height=\"20\" width=\"20\" style=\"display: none\" src=\"/assets/internal-visibility.svg\"/>\n    <text>private</text>\n</div>'"},{"name":"Esther Priel","email":"esther@neuromagen.com","phone":"0502029610","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4M_btNEIDA","bounced":false,"claimed":0,"founder":1,"urlname":"esther-priel-1","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDg783I-wkM","position":"Founder, CEO & CSO","last_name":"Priel","claimtoken":"XIv8DcHY7yUfhCVz79gwRhDHHmdeA4lORuaqgCAg7kGe841gYAvp1a","first_name":"Esther","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/esther-priel-055a60144","unsubscribed":false,"is_activeuser":1,"additionalemail":"priel@bgu.ac.il","claimedemaildate":"2025-01-07 12:21:24.000000","initials":"EP","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Daniella  Bouhnik","email":"daniella@neuromagen.com","phone":"","gender":"Female","userid":"jbLcscrOvTjJbbWn1Gpd2BQTvB0vWhotNThbGkHPeSmz9F1ckajLKK","bounced":false,"claimed":null,"founder":0,"urlname":"daniella-bouhnik","visible":1,"memberid":"HmShQCvD8SjY5ygmABI3CNGPiZxKmzOk567XMIcvupSye85IXIc8CN","position":"Chief Operating Officer","last_name":"Bouhnik","claimtoken":"4Sl1Krpgm3FOszCOEXbMpCbE7Mn4itOI9WmUGiKZOf4L4bc4MVa9mP","first_name":"Daniella ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/daniellabouhnik/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2023-11-24 19:07:13.000000","initials":"DB","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Helena  Grinberg-Rashi","email":"helena@neuromagen.com","phone":"","gender":"Female","userid":"hyhQfAyoFdzaJl3OlIwf2cocZDWUG0npP3lIIpQvXqsyDTmpgB1kCL","bounced":false,"claimed":null,"founder":0,"urlname":"helena-grinberg-rashi-1","visible":1,"memberid":"ZO7h6Yma8a8GYAY3Y2bViFU6Xiy8DqkL65GtJgfY7q7yRXH1h2LIxt","position":"Senior Clinical and Regulatory Advisor","last_name":"Grinberg-Rashi","claimtoken":"lWEs0gibpNHU0kDmyNYBCiaEyKElVglKoOgmt34rrYefP9Zp6HrXD6","first_name":"Helena ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/dr-helena-gr/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2023-01-20 02:40:02.000000","initials":"HG","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Pharmaceuticals","sectorverify":null,"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoNqyo8cLDA","fullname":"Yotam Maman"},"biverifydate":"2021-07-27T00:00:00.000Z","crunchbaseid":"neuromagen-pharma","lastupdator":"Yanina Wainscheinker","lastupdator_email":"yanina.wainscheinker@sncentral.org","creator":"Jenny Sotnik-Talisman","creator_email":"genys30@yahoo.com","createdate":"2021-07-05T00:00:00.000Z","biverification":"Yotam Maman","sectorverification":null,"affiliatedOrganizations":null,"timeline":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJC0jfaICAw","date":"Mar 2022","amount":"$500K","source":"https://www.prnewswire.com/il/news-releases/neuromagen-pharma-announces-the-approval-of-a-nis-1-8m-budget-from-the-israel-innovation-authority-rd-fund-incentive-program-301506255.html","eventtype":"GrantEvent","granttype":1,"investment":[{"name":"IIA","type":"Government","amount":0,"hidden":false,"country":"Israel","fullurl":"/company_page/iia","logokey":null,"tagline":"","urlname":"/company_page/iia","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOChyaugCgw","fundingtype":"Government","leadpartner":null,"investmentid":"60e2981e-d3e3-48d5-830d-f5a01320f01d","fundingsubtype":"","investorislead":0,"amountvisibility":"Public","isextensionround":null,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/startups-icon.svg","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJCw6cegCAw","date":"Nov 2021","amount":"$2M","source":"https://in.bgu.ac.il/en/pages/news/ALS_neuromagen.aspx,  https://www-timesofisrael-com.cdn.ampproject.org/c/s/www.timesofisrael.com/israeli-drug-that-slowed-alzheimers-als-in-mice-gets-funding-to-start-trials/amp/","eventtype":"FundingRoundEvent","investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":2000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODXtcy_CAw","hub":"Oazis","date":"Feb 2021","batch":"2","amount":"Undisclosed","hub_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4JaWhfQJDA","source":"https://www.bgu-oazis.com/ourportfolio","enddate":"Jun 2021","hub_type":"Accelerator","eventtype":"GraduationEvent","hub_hidden":false,"investment":[],"hub_fullurl":"/program_page/oazis","hub_logokey":"$vehrSO5ygtI3cAYI5cyjd6z0wAZNqFqV8qAfGs3WTBwPQIPbrfiton","hub_urlname":"/program_page/oazis","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"style":"","hiddenCompanyTooltip":"","hub_logourl":"https://storage.googleapis.com/clean-finder-353810/$vehrSO5ygtI3cAYI5cyjd6z0wAZNqFqV8qAfGs3WTBwPQIPbrfiton","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"5/2021","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"Neuromagen Pharma","logourl":"https://storage.googleapis.com/clean-finder-353810/$YrmQfKyyhQ3IhVcQz0rKLzEebtD5ioO9QNNnZpG9XfBA9xgb1UNmHP","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$YrmQfKyyhQ3IhVcQz0rKLzEebtD5ioO9QNNnZpG9XfBA9xgb1UNmHP","seoabout":"Neuromagen Pharma is a pharmaceutical company developing a new class of innovative small molecules that activate telomerase reverse transcriptase (TERT), a...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":4,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Cells","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA","classificationName":"coretechnology"},{"depth":2,"name":"Molecules","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationDelimited":["IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA>Cells#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA>Molecules#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA"],"classificationsViewModel":"|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA|2:>TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA/Cells#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA|2:>TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA/Molecules#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Pharma & Medical Biotechnology","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Drugs Discovery & Development","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Drugs Discovery & Development"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Life Sciences","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences","children":[{"title":"Pharmaceuticals","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Pharmaceuticals"}]}]}],"coreTechnology":[{"title":"Biologicals","key":"0-0","path":"TechnologyClassificationModel>Biologicals","children":[{"title":"Cells","key":"0-0-0","path":"TechnologyClassificationModel>Biologicals>Cells"},{"title":"Molecules","key":"0-0-1","path":"TechnologyClassificationModel>Biologicals>Molecules"}]}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Cells","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA","classificationName":"coretechnology"},{"depth":2,"name":"Molecules","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Pharma & Medical Biotechnology","Drugs Discovery & Development"],"coreTechnology":["Biologicals","Cells","Molecules"],"targetCustomer":["Healthcare & Life Sciences","Life Sciences","Pharmaceuticals"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"none","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJCw6cegCAw","date":"Nov 2021","amount":"$2M","source":"https://in.bgu.ac.il/en/pages/news/ALS_neuromagen.aspx,  https://www-timesofisrael-com.cdn.ampproject.org/c/s/www.timesofisrael.com/israeli-drug-that-slowed-alzheimers-als-in-mice-gets-funding-to-start-trials/amp/","eventtype":"FundingRoundEvent","investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":2000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJC0jfaICAw","date":"Mar 2022","amount":"$500K","source":"https://www.prnewswire.com/il/news-releases/neuromagen-pharma-announces-the-approval-of-a-nis-1-8m-budget-from-the-israel-innovation-authority-rd-fund-incentive-program-301506255.html","eventtype":"GrantEvent","granttype":1,"investment":[{"name":"IIA","type":"Government","amount":0,"hidden":false,"country":"Israel","fullurl":"/company_page/iia","logokey":null,"tagline":"","urlname":"/company_page/iia","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOChyaugCgw","fundingtype":"Government","leadpartner":null,"investmentid":"60e2981e-d3e3-48d5-830d-f5a01320f01d","fundingsubtype":"","investorislead":0,"amountvisibility":"Public","isextensionround":null,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/startups-icon.svg","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"merger_acquisitions":[],"others":[]}}